What is the enterprise value (EV) for Natera, Inc. (NTRA)?

The enterprise value (EV) for NTRA stock is $57.77B.

Natera (NTRA) Enterprise Value: History & Chart

Compare

Natera, Inc.(NTRA)

Medical - Diagnostics & Research · Austin, TX

$410.35+1.88 (+0.46%)

Delayed quote: Oct 2, 2026, 4:00 PM EDT

Compare

About Natera, Inc.

Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.

Austin, TX

6,138 employees

www.natera.com

Healthcare / Medical - Diagnostics & Research

Sector: Healthcare
Industry: Medical - Diagnostics & Research
CEO: Steven Leonard Chapman

View full financials

NAME	MARKET CAP	ENTERPRISE VALUE (EV)
Natera, Inc. (NTRA)	$58.77B	$57.77B
Cencora, Inc. (COR)vs ›	$60.13B	$69.04B
Boston Scientific Corporation (BSX)vs ›	$63.32B	$75.40B
Cardinal Health, Inc. (CAH)vs ›	$53.47B	$58.56B
Edwards Lifesciences Corporation (EW)vs ›	$49.03B	$46.83B
Becton, Dickinson and Company (BDX)vs ›	$48.72B	$64.82B
Agilent Technologies, Inc. (A)vs ›	$47.38B	$49.57B
Humana Inc. (HUM)vs ›	$46.63B	$53.99B
Cigna Corporation (CI)vs ›	$71.48B	$97.06B
Teva Pharmaceutical Industries Limited (TEVA)vs ›	$46.04B	$59.26B

NAME

MARKET CAP

ENTERPRISE VALUE (EV)

Natera, Inc. (NTRA)

$58.77B

$57.77B

Cencora, Inc. (COR)vs ›

$60.13B

$69.04B

Boston Scientific Corporation (BSX)vs ›

$63.32B

$75.40B